The tweet was deleted by the author.
But we saved everything 🙂.
Candel Therapeutics, Inc. has unveiled new long term follow up data from its phase 3 trial of aglatimagene besadenovec (CAN-2409) targeting localized prostate cancer.
Chief Executive Officer Paul Peter Tak engaged in an interview with Endpoints News reporter Nicole DeFeudis to discuss the clinical findings. The update highlights the company’s continued progress in immunotherapy and cancer research, with attention focused on the therapy’s impact in prostate cancer management. Further peer-reviewed publication and clinical commentary are anticipated as the field digests these trial outcomes.
View post on X Loading...
Earlier results from Candel’s phase 3 prostate cancer trial showed an 80.4 percent complete response rate, surpassing outcomes in the placebo group, according to a prior report. At BioEquityEurope this year, CEO Paul Peter Tak called for strengthening patient engagement to drive innovation in drug discovery, as noted in a previous panel discussion. The company continues to advance its research pipeline alongside these ongoing clinical updates.